Education
About Us
Working with TipRanks
Follow Us
Cullinan Management (CGEM)
NASDAQ:CGEM
CGEM Stock Chart & Stats
$12.23
-$0.28(-2.38%)
At close: 4:00 PM EST
$12.23
-$0.28(-2.38%)
Day’s Range― - ―
52-Week Range$5.68 - $13.43
Previous CloseN/A
Volume73.34K
Average Volume (3M)654.46K
Market Cap
$722.50M
Enterprise Value$589.68M
Total Cash (Recent Filing)$332.60M
Total Debt (Recent Filing)$1.19M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Mar 05, 2026EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding59,076,260
10 Day Avg. Volume667,737
30 Day Avg. Volume654,460
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)1.11
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.76K
Enterprise Value/Ebitda-2.50
Forecast
1Y Price Target
$31.50Price Target Upside157.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.11
Revenue Forecast (FY)$26.65M
Bulls Say, Bears Say
Bulls Say
AML Clinical ProgressDurable monotherapy responses and activity in TP53‑mutated acute myeloid leukemia support CLN‑049's potential across AML patients and underpin the planned Phase 1/2 combination trial initiation in 2026.
Autoimmune Clinical ReadoutsUpcoming clinical readouts for CLN-978 in rheumatoid arthritis, systemic lupus erythematosus, and Sjögren’s disease could show tissue B‑cell depletion and early therapeutic activity that materially alters the company outlook.
Regulatory Submission And PartnershipA rolling NDA submission and completed filing for zipalertinib in EGFR exon 20 insertion lung cancer, together with an established partner holding ex‑US rights, could enable accelerated approval and a clear commercialization pathway.
Bears Say
Competitive Pressure On AdoptionCompetition from other antibodies and cell therapies, plus a competing EGFR agent that can be used as a single‑agent in first‑line settings, could limit uptake of the company's targeted treatments.
Early‑stage Development RiskSeveral T‑cell engager programs remain in early clinical stages, requiring dose optimization and successful pivotal trials before translating early signals into broad commercial opportunity.
Investor Sentiment And Operational RisksShares trading below the price of a recent equity offering, together with investor impatience, risks of slow trial enrollment, trial delays, and potential future dilution, increase downside volatility for the stock.
Cullinan Management News
CGEM FAQ
What was Cullinan Management’s price range in the past 12 months?
Cullinan Management lowest stock price was $5.68 and its highest was $13.43 in the past 12 months.
What is Cullinan Management’s market cap?
Cullinan Management’s market cap is $722.50M.
When is Cullinan Management’s upcoming earnings report date?
Cullinan Management’s upcoming earnings report date is Mar 05, 2026 which is in 23 days.
How were Cullinan Management’s earnings last quarter?
Cullinan Management released its earnings results on Nov 06, 2025. The company reported -$0.77 earnings per share for the quarter, beating the consensus estimate of -$0.947 by $0.177.
Is Cullinan Management overvalued?
According to Wall Street analysts Cullinan Management’s price is currently Undervalued.
Does Cullinan Management pay dividends?
Cullinan Management does not currently pay dividends.
What is Cullinan Management’s EPS estimate?
Cullinan Management’s EPS estimate is -0.8.
How many shares outstanding does Cullinan Management have?
Cullinan Management has 59,076,260 shares outstanding.
What happened to Cullinan Management’s price movement after its last earnings report?
Cullinan Management reported an EPS of -$0.77 in its last earnings report, beating expectations of -$0.947. Following the earnings report the stock price went up 0.547%.
Which hedge fund is a major shareholder of Cullinan Management?
Currently, no hedge funds are holding shares in CGEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cullinan Management Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.50 (157.56% Upside)
$31.50 (157.56% Upside)
Blogger Sentiment
Bullish
CGEM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 903.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $172.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.16%
12-Months-Change
Fundamentals
Return on Equity
-40.18%
Trailing 12-Months
Asset Growth
-25.89%
Trailing 12-Months
Company Description
Cullinan Management
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
CGEM Stock 12 Month Forecast
Average Price Target
$31.50
▲(157.56% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---